Major AI, Robotics and Biotech Funding Rounds in H2 2026
Recent financing activity saw multi‑hundred‑million investments in AI hardware, large AI fundraisings, humanoid‑robot valuations and early‑stage biotech gene‑editing programmes.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Xsight Labs closed a funding round of more than $300 million that valued the Israeli fabless semiconductor firm at $2.8 billion post‑money. The round was led by Fidelity Management & Research Company and included participation from Intel Capital, Battery Ventures, T. Rowe Price, Valor Equity Partners, Atreides Management and other new and existing investors [1][4]. Proceeds will accelerate the multi‑generational roadmap for its programmable Ethernet switches and data‑processing units, expand engineering and customer‑support teams across the US, Israel, Europe and Asia, and scale manufacturing and supply‑chain capacity to meet Tier‑1 orders.
Menlo Ventures announced the closure of $3 billion in new capital across two funds, the largest raise in its 50‑year history. Menlo Ventures XVII will focus on seed and Series A investments, while Menlo Inflection IV will provide growth capital for Series B and later stages, both targeting the artificial‑intelligence market from foundational models and infrastructure to enterprise, healthcare and consumer applications [2]. The expanded capital pool is intended to give the firm flexibility to back companies from formation through hyper‑growth, as illustrated by its existing AI portfolio that includes Anthropic, Lovable, Suno, OpenRouter, Wispr, Fireworks AI, Modal, Skild AI and Goodfire.
The Funding Weekly roundup highlighted several large AI investments in Q2 2026. Amazon completed a total $50 billion investment in OpenAI, including $13.7 billion poured into OpenAI and $11.3 billion into Anthropic during the quarter [3]. Moonshot AI raised $3.5 billion in a round that lifted its valuation to $35 billion. Simile secured a $200 million Series B at a $2 billion post‑money valuation, while voice‑technology startup Fish Audio closed a $50 million seed round. The same report also noted robotics financing, such as a $200 million Series C for Standard Bots, a $71 million seed for Enigma and over ¥100 million raised by Quantum Dynamics, underscoring continued capital flow to AI‑adjacent hardware.
Robotics
Figure AI remains the most valuable pure‑play humanoid‑robot company after a Series C in September 2025 raised over $1 billion and set a post‑money valuation of roughly $39 billion [6]. Germany’s NEURA Robotics announced a Series C financing of up to $1.4 billion in June 2026, which the Financial Times valued the firm at about $7 billion. Unitree is preparing a Shanghai STAR‑Market IPO that would imply a valuation between $5.9 billion and $7 billion, while AgiBot targets a Hong Kong IPO valuation of $5.1‑$6.4 billion. South‑Korean public company Rainbow Robotics reported a market capitalisation of approximately $6 billion, completing the current ranking of leading humanoid‑robot firms.
Genetic Engineering
Immitra Bio completed an upsized pre‑seed financing of CHF 2.4 million to advance its in‑vivo gene‑editing platform and its lead candidate for an inherited anemia [5]. The round was led by Backbone Ventures and co‑led by OCCIDENT, with participation from Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, the ETH Foundation and private investors. CHF 2.25 million came from venture capital and private sources and CHF 150 000 from non‑dilutive funding. The capital will primarily fund pre‑clinical proof‑of‑concept studies for IB‑003, discovery and validation work across the pipeline, and further refinement of the digital target‑identification platform.
The BIO 2026 panel reported that 40 biotech companies secured mega‑rounds (over $100 million) in the first half of 2026, up from 33 the previous year, amid a 23 percent year‑over‑year increase in venture capital to $23 billion in 2025 [7]. Highlighted deals included SonoThera’s $125 million Series B for its bubble‑based gene‑delivery system, Cognito Therapeutics’ $105 million Series C after expanding its Alzheimer’s programme to a 673‑patient Phase 3, and Enveda’s $550 million raise citing a “China‑like efficiency” model. The discussion underscored that robust clinical data and efficient development pipelines remain key criteria for investors seeking large‑scale biotech funding.